DNA vaccines: safety aspect assessment and regulation
- PMID: 17058502
DNA vaccines: safety aspect assessment and regulation
Abstract
For licensing purposes, besides the immunogenic aspects, deoxyribonucleic acid (DNA) vaccines present safety considerations that must be critically assessed during preclinical or/and clinical safety studies. The major concerns with regard to safety are integration of the plasmid DNA into the host genome, adverse immunopathological effects, the formation of anti-DNA antibodies resulting in auto-immune disease and the use of novel molecular adjuvants. Moreover, for veterinary vaccines intended to be used in husbandry animals, food safety aspects will become an important issue. All new vaccine candidates should therefore be thoroughly tested in target animals, keeping in mind that for food producing animals, the products will be consumed. Finally, a further safety aspect of interest concerns the possible spread of genetic material to the environment, by the potential transformation of the environmental microflora with only a few copies of complete or fragmented plasmid. These are issues that need to be considered in the final scientific decisions underpinning the registration of vaccines. Thus, to establish criteria for guidance and regulations for industry and licensing authorities, a project has been initiated to assess such risks of plasmid DNA vaccinations. Major emphasis will be placed on aspects such as the biodistribution of plasmid in vaccinated animals. This paper is intended as a contribution to the debate on the use of biotechnology in the future and should facilitate further discussions on the various safety aspects of DNA-based immunisations.
Similar articles
-
Risk assessment in new and conventional vaccines.Dev Biol (Basel). 2006;126:253-9; discussion 327. Dev Biol (Basel). 2006. PMID: 17058501
-
Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.Food Chem Toxicol. 2008 Mar;46 Suppl 1:S2-70. doi: 10.1016/j.fct.2008.02.008. Epub 2008 Feb 13. Food Chem Toxicol. 2008. PMID: 18328408 Review.
-
European Union guidance on the quality, safety and efficacy of DNA vaccines and regulatory requirements.Dev Biol (Basel). 2000;104:53-6. Dev Biol (Basel). 2000. PMID: 11713824
-
Regulation and review of DNA vaccine products.Dev Biol (Basel). 2000;104:57-62. Dev Biol (Basel). 2000. PMID: 11713825
-
Assuring the quality, safety, and efficacy of DNA vaccines.Mol Biotechnol. 2001 Feb;17(2):143-9. doi: 10.1385/MB:17:2:143. Mol Biotechnol. 2001. PMID: 11395863 Review.
Cited by
-
Virosome-based nanovaccines; a promising bioinspiration and biomimetic approach for preventing viral diseases: A review.Int J Biol Macromol. 2021 Jul 1;182:648-658. doi: 10.1016/j.ijbiomac.2021.04.005. Epub 2021 Apr 16. Int J Biol Macromol. 2021. PMID: 33862071 Free PMC article. Review.
-
The efficacy, biodistribution and safety of an inhibin DNA vaccine delivered by attenuated Salmonella choleraesuis.Microb Biotechnol. 2018 Jan;11(1):248-256. doi: 10.1111/1751-7915.13029. Epub 2017 Dec 4. Microb Biotechnol. 2018. PMID: 29205848 Free PMC article.
-
The Promising Potential of Reverse Vaccinology-Based Next-Generation Vaccine Development over Conventional Vaccines against Antibiotic-Resistant Bacteria.Vaccines (Basel). 2023 Jul 20;11(7):1264. doi: 10.3390/vaccines11071264. Vaccines (Basel). 2023. PMID: 37515079 Free PMC article. Review.
-
Vaccination with a codon-optimized A27L-containing plasmid decreases virus replication and dissemination after vaccinia virus challenge.Vaccine. 2017 Oct 20;35(44):6007-6014. doi: 10.1016/j.vaccine.2017.05.091. Epub 2017 Jun 16. Vaccine. 2017. PMID: 28629922 Free PMC article.
-
Short Carbon Nanotube-Based Delivery of mRNA for HIV-1 Vaccines.Biomolecules. 2023 Jul 7;13(7):1088. doi: 10.3390/biom13071088. Biomolecules. 2023. PMID: 37509124 Free PMC article.